

Medium Throughput Automation of two Cytotoxicity Assays with the Eppendorf *epMotion*® 5075t

Eric Gancarek, Sandrine Hamels, Muriel Art

Eppendorf Application Technologies S.A., Namur, Belgium

Abstract

Cell based Assays (CBA) are widely used tools in life science research and also drug development. As these assays are normally carried out in multiple plates starting from 96 well to even 1536 well formats, automation is regarded as highly useful to increase robustness and reproducibility of the obtained results. Here we demonstrate that the Eppendorf *epMotion* 5075t can perfectly be used for medium throughput automation of two different commercially available Cytotoxicity Assays: the Vybrant® Cytotoxicity Assay (Molecular Probes®, Life Technologies®) and CytoTox-Fluor™ (Promega®). In comparison to a manual procedure the assay robustness

and data consistency could be increased by using the *epMotion*. For both Cytotoxicity Assay kits the entire workflow from cell seeding to the final addition of the respective assay reagents as carried out automatically on the *epMotion* 5075t. The workstation was equipped with the optional CleanCap module that includes HEPA filters and UV lights, thus allowing to maintain a sufficiently clean environment for cell culture work. In total the experiments described in this study emphasize the usability of the *epMotion* liquid handling workstation for cell based assays.

Introduction

Drug discovery and development is a long and costly process which can be divided into four different phases: early discovery, late discovery, preclinical and clinical. About 10–15 years are necessary to develop a new medicine from the moment it is discovered to when it is available for patients. The highest cost in terms of time occurs in early and late discovery while the highest cost in terms of money is concentrated on preclinical and clinical phases. Among all potential candidates entering into the development pipeline, it has been estimated that only 1 out of 10,000 candidates really reaches the market. As costs associated with this failure considerably increase when compounds advance within this process, identifying risks in the early development phases has become essential for pharmaceutical

companies [1]. There are many reasons inducing drug candidate failure during development. The molecule exclusion can be due to poor biopharmaceutical properties as solubility and stability but the two major causes of cessation are unacceptable drug's efficacy and toxicity. Historically, toxicity testing was performed just before clinical trials and generally involved animal models. To optimize drug development processes, scientists reviewed their strategy and moved toxicity tests into the early stage of development. During this phase, the number of potentially therapeutic compounds is still extremely large and cannot be tackled by methods based on animals. The emergence of cytotoxicity cell-based assays permitted to support this new developmental approach.

Cytotoxicity assays conducted during early development steps have to face various challenges. Sensitivity is crucial but the assay has also to be simple, robust, rapid and cost-effective. To allow medium or high-throughput screening (HTS), assay automation using 96-, 384- or even 1536-well formats has to be possible without affecting reproducibility and statistical significance of data [2]. The most common way to measure the cytotoxic impact of a compound is to evaluate the loss of cellular membrane integrity associated

with cell death. Biomarkers generally used are constitutive enzymes released into the extracellular environment after membrane damage [3]. Assays used in this study, Vybrant Cytotoxicity Assay kit from Life Technologies and CytoTox-Fluor Cytotoxicity Assay from Promega, are based on this principle and allowed to demonstrate the ability to implement a cytotoxicity cell-based assay on the Eppendorf *epMotion* 5075t.

Material and Methods

Materials

Automation and Detection Instruments

- > *epMotion* 5075t with CleanCap configuration option including UV lights and HEPA filters (Eppendorf, order no.: 5075 000.302 and 5075 751.607)
- > Gripper (Eppendorf, order no.: 5282 000.018)
- > TS50 pipetting tool (Eppendorf, order no.: 5280 000.010)
- > TM50-8 pipetting tool (Eppendorf, order no.: 5280 000.215)
- > TM1000-8 pipetting tool (Eppendorf, order no.: 5280 000.258)
- > ReservoirRack for *epMotion* (Eppendorf, order no.: 5075 754.002)
- > PlateReader AF2200 (Eppendorf, order no.: 6141 000.002)
- > Galaxy® 48 R incubator (Eppendorf, order no.: CO48R-230-000)

Consumables

- > epT.I.P.S.® Motion 50 µL Filter, sterile (Eppendorf, order no.: 0030 015.215)
- > epT.I.P.S. Motion 1000 µL Filter, sterile (Eppendorf, order no.: 0030 015.258)
- > *epMotion* Reservoir 30 mL and 100 mL (Eppendorf, order no.: 0030 126.505 – 0030 126.513)
- > Reservoir Rack Module TC, for use in *epMotion* Reservoir Racks, temperable, 4 x Eppendorf Safe-Lock Tubes 0.5/1.5/2.0 mL (Eppendorf, order no.: 5075 799.081)
- > Eppendorf Safe-Lock Tubes, 1.5 mL (Eppendorf, order no.: 0030 120.086)
- > Eppendorf Deepwell Plate 96/1000 µL (Eppendorf, order no.: 0030 502.205)

Cell Assay

- > HepG2 human liver hepatocellular carcinoma cell line (DSMZ, order no.: ACC 180) cultivated in RPMI 1640 medium supplemented with 10 % FBS and 1 % Penicillin-Streptomycin
- > Cell Imaging Plate (Eppendorf, order no.: 0030 741.013)
- > Ionomycin calcium salt (Enzo Life Sciences®, order no.: ALX-450-007) dissolved in DMSO
- > Vybrant Cytotoxicity Assay kit (Life Technologies, order no.: V-23111)
- > CytoTox-Fluor Cytotoxicity Assay (Promega, order no.: G9261)

Methods for automated Cell-based assay

The complete workflow is programmed to process three 96-well plates in parallel and is divided into three *epMotion* methods. For the first two methods, the *epMotion* 5075t surfaces and tools are cleaned using a disinfection solution (UMONIUM^{38®}; Laboratoire Huckert's International). UV-lights and HEPA filters are started one hour before using the workstation. The UV-lights stopped automatically after 15 minutes. At the end of each method, a user intervention is required to hand the plates over to downstream steps (incubation, reading).

Method 1:

Cell seeding is performed during this first protocol step. Adherent HepG2 cells are seeded into 96-well Cell Imaging plates at 30,000 cells per well. Before starting the *epMotion* method 1, a cell solution at the appropriate concentration (30,000 cells per 90 µL) is prepared in a sterile tube and transferred to a sterile autoclaved *epMotion* reservoir of

100 mL on the *epMotion* 5075t. Cell culture medium, used as blank, is transferred in a sterile *epMotion* reservoir of 30 mL. These steps need to be performed under sterile cell culture conditions. The method 1 generates the dispensing of 90 µL of cells per well in column 1 to 11 in three 96-well microplates and 90 µL of culture medium without cells in column 12 in these three plates. At the end of the program, the lid is manually replaced on the plates and the plates are placed into the Galaxy CO₂ incubator at 37 °C for 24 hours.

Worktable Layout

Position	Item
A2	epT.I.P.S. Motion 1000 µL Filter
B2	Reservoir Rack
B3	Cell Imaging Plate (96-well plate)
B4	Cell Imaging Plate (96-well plate)
B5	Cell Imaging Plate (96-well plate)




Figure 1: Worktable layout for method 1


Method 2:

The goal of the second method is to generate the concentration curve of the cytotoxic agent Ionomycin. Concentration range is between 0.03 µM and 100 µM and 16 increasing concentrations are used for inducing cell death. The concentration curve is produced by using three different dilution steps and performed in a Deepwell plate. The first dilution is performed into DMSO 99.9 % vehicle solution and the second dilution into culture medium without FBS for generating 16 ionomycin concentrations 10 times more concentrated than desired. The last dilution is performed into culture medium with 10 % FBS. Culture medium without toxic agent and DMSO being used as negative control are also added into the Deepwell Plate. At the end of this first part, the 96-well plates seeded with the cells are placed on the worktable. The second part starts with the culture medium removal from the three 96-well plates. 100 µL of each Ionomycin concentration solution is dispensed from the Deepwell plate to the 96-well plates.

The final vehicle (DMSO) concentration did not exceed 1 % and was equivalent for all Ionomycin concentrations tested. At the end of the method, the lid is manually replaced on the plates. With the cellular model used for this study (HepG2 cells), seeded plates were incubated 7 hours at 37 °C (5 % CO₂).

Worktable Layout

Position	Item
A2	epT.I.P.S. Motion 1000 µL Filter
A3	epT.I.P.S. Motion 1000 µL Filter
B1	epT.I.P.S. Motion 50 µL Filter
B2	Reservoir Rack
B3	Cell Imaging Plate (96-well plate)
B4	Cell Imaging Plate (96-well plate)
B5	Cell Imaging Plate (96-well plate)
C3	Deepwell Plate 96/1000 µL



Method 3:

After incubation, the plates are removed from the CO₂ incubator. When the Vybrant Cytotoxicity Assay kit is used, this method includes the dispensing of 100 µL freshly prepared 2 x resazurin reaction mixture to each well of three 96-well plates. The plates are transferred to the TMX position and mixed at 500 rpm for 30 sec. At the end of this method, the lid is manually replaced on the plates and the plates are incubated at 37 °C in the Galaxy incubator at humidified 5 % CO₂ atmosphere for 25 minutes. Fluorescence generated by the resazurin metabolism was read in each well (excitation at 535 nm and emission at 595 nm) with the PlateReader AF2200. When the CytoTox-Fluor Cytotoxicity Assay kit is used, this method includes the dispensing of 100 µL of CytoTox-Fluor Cytotoxicity Assay Reagent to each well of three 96-well plates. The

plates are transferred to the TMX position and mixed at 500 rpm for 30 sec. With this assay, plates are incubated at room temperature for 30 minutes. Fluorescence generated by the »dead-cell protease activity« was read in each well (excitation at 485 nm and emission at 535 nm).

Worktable Layout

Position	Item
A2	epT.I.P.S. Motion 1000 µL Filter
A3	epT.I.P.S. Motion 50 µL Filter
B2	Reservoir Rack
B3	Cell Imaging Plate (96-well plate)
B4	Cell Imaging Plate (96-well plate)
B5	Cell Imaging Plate (96-well plate)




Figure 3: Worktable layout for method 3

Those methods allow the generation of three 96-well plates. In each plate, 16 cytotoxic agent concentrations are

evaluated in five replicates. Blank and negative controls are also included.

Results and Discussion

Automation of a cytotoxicity cell-based assay was initially studied by implementing the Vybrant Cytotoxicity Assay on the ep*Motion* 5075t. This kit measures the release of the cytosolic enzyme glucose 6-phosphate dehydrogenase (G6PD) into the extracellular environment. G6PD is detected through a two-step enzymatic process that leads to the reduction of resazurin to red-fluorescent resorufin [4]. As G6PD is an abundant enzyme present in all cells and as resazurin is non-radioactive, water-soluble and stable in most culture media, a kit based on this principle represents a good candidate for automation [5]. Through the CleanCap configuration available for the Eppendorf ep*Motion* 5075t, the workstation enclosure can be used to maintain a clean environment. For steps requiring sterile environment, ep*Motion* 5075t surface and tools were previously cleaned with Umonium³⁸ disinfectant. Therefore, the complete cell-based assay protocol, including cell seeding, toxic compound dilution curve preparation and assay reagent addition, can be accomplished with the automation platform. Only plate incubation at 37 °C and data reading are carried out offline.

Comparison of manual versus automated cell-based assay performances

The automation of the Vybrant Cytotoxicity Assay with the ep*Motion* 5075t was validated by using HepG2 cell line as cellular model system. Those cells, derived from liver tissue and commonly used in toxicology, were treated with an Ionomycin dose-response curve. Ionomycin is a bacterial ionophore used in research to affect calcium transport across cell membranes. Prolonged molecule exposure on cells results in a dose-dependent cell viability decrease and a cytotoxicity increase. In parallel, the assay was performed manually using the same cellular model. Five

replicates of each Ionomycin concentration were tested and three plates were processed in parallel. Results obtained demonstrated the capability to automate the Vybrant Cytotoxicity Assay on the ep*Motion* 5075t (Table 1).

Table 1: Comparison of manual and automated Vybrant Cytotoxicity Assay.

		Z' factor	Global intra-plate CV (n = 5)	Global inter-plate CV (n = 3)
ep <i>Motion</i>	P 1	0.90	6.2 %	3.90 %
	P 2	0.82	5.5 %	
	P 3	0.77	5.7 %	
Manual	P 1	0.56	13.3 %	16.8 %
	P 2	0.75	11.9 %	
	P 3	0.78	8.4 %	

To evaluate the capability of a cell-based assay to be automated, a statistical value called Z'-factor is commonly used as indicator of assay robustness. A value above 0.5 is the sign of an excellent assay quality [6]. All assays performed on the ep*Motion* 5075t had a Z'-factor value higher than 0.75 indicating that automated assays are as robust as assays performed manually.

Besides an excellent robustness, a significant advantage offered by automating the Vybrant Cytotoxicity Assay is the decrease of the assay variability. Indeed, as intra- and inter-plate precision values show (Table 1), the assay reproducibility is highly improved by reducing human interaction. With the cellular model used in this study, the intra-plate assay is almost 2 times more reproducible when automated. For the inter-plate reproducibility, the improvement is even greater.

Implementation of Various Cytotoxicity assay kits

The number of commercially available cytotoxicity assay kits is very large. Workstations proposed as automation solution should consequently be compatible with various methods developed for measuring toxicity effect. Resazurin added for monitoring the activity of G6PD released by death cells is a permeable indicator also used to evaluate cell viability. It is a major component of viability cell-based assay kits as the CellTiter-Blue® Cell Viability Assay from Promega. Its use during a cytotoxicity assay implies that a certain amount of resazurin could be reduced by cells which are still viable. For this reason, scientists could prefer an alternative biomarker. The CytoTox-Fluor Cytotoxicity Assay kit provided by Promega measures a protease activity associated with cytotoxicity. The enzyme substrate used is a fluorogenic peptide (bis-alanyl-alanyl-phenylalanyl-rhodamine 110; bis-AAF-R110) which cannot cross the intact membrane of live cells. Consequently, signals generated can only be due to proteases released from cells that lost membrane

integrity [7]. The same cellular model (HepG2 cells treated with a concentration curve of Ionomycin) was used to compare automation of both assays. Z' factor and signal-to-background ratio have been evaluated (Table 2).

Table 2: Comparison of Vybrant Cytotoxicity Assay and CytoTox-Fluor Cytotoxicity Assay on epMotion

Assay	Z' factor	S/B value
Vybrant Cytotoxicity Assay	0.70	5.00
CytoTox-Fluor Cytotoxicity Assay	0.67	7.10

As expected, the signal-to-background ratio is slightly improved when the enzyme substrate used is not able to enter into viable cells. Z' factor values clearly prove that with the epMotion 5075t, the robustness of cytotoxicity assays is guaranteed independent of the kit.

Conclusion

During the long drug discovery process, researchers rely on various parameters as viability, apoptosis and cytotoxicity to get biological information and to make their decisions. The capability to automate cell-based assays designed to monitor apoptosis [8] and cell viability [9] on the Eppendorf epMotion 5075t has already been demonstrated. In the present Application Note, we show that also cytotoxicity assays can be successfully automated with the same liquid handling workstation. Assay implementation has been evaluated with 2 commercial kits measuring the activity of an enzyme, released from cells after they were subjected to membrane damages: Vybrant Cytotoxicity Assay kit from

Life Technologies and CytoTox-Fluor Cytotoxicity Assay from Promega. All assays performed had a Z'-factor value greater than 0.65, indicating the excellent robustness of the assay. Comparison to the manual method confirmed that automation with the epMotion 5075t significantly increases the assay reproducibility while reducing the hands-on time. With robustness and reproducibility being guaranteed, automating cell-based assays on the epMotion 5075t represents a perfect solution for scientists interested in a low to medium-throughput screening, no matter which cell response is of interest.

References

- [1] McKim J.M. Building a tiered approach to *in vitro* predictive toxicity screening: a focus on assays with *in vivo* relevance. *Combinatorial Chemistry & High Throughput Screening* 2010; 13: 188–206.
- [2] Crouch S.P.M. and Slater K.J. High-throughput cytotoxicity screening: hit and miss. *Drug Discovery Today* 2001; 6: S48–S53.
- [3] Niles A.L., Moravec R.A. and Riss T.L. *In vitro* viability and cytotoxicity testing and same-well multi-parametric combinations for high throughput screening. *Current Chemicals Genomics* 2009; 3: 33–41.
- [4] Vybrant® Cytotoxicity Assay kit *Product information* MP23111, Molecular Probes, Inc.
- [5] Batchelor R.H. and Zhou M. Use of cellular glucose-6-phosphate dehydrogenase for cell quantification: applications in cytotoxicity and apoptosis assays. *Analytical Biochemistry* 2004; 329: 35–42.
- [6] Zhang J, Chung T, Oldenburg K. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. *J. Biomol. Screening* 2009; 4:67–73.
- [7] CytoTox-Fluor™ Cytotoxicity Assay *Technical Bulletin* #TB350, Promega Corporation.
- [8] Automated Cell-based Apoptosis Assays with the Eppendorf epMotion® 5075t increases the reproducibility Eppendorf Application Note 329, 2014; www.eppendorf.com
- [9] Reliable and robust automation of Cell Viability Assays with the epMotion® 5075t Application Note 344, 2014; www.eppendorf.com
- [10] Hardware Manual Eppendorf epMotion® 5075t. www.eppendorf.com

Ordering information

Description	Order no. international	Order no. North America
epMotion® 5075t with CleanCap configuration option including UV lights and HEPA filters	5076 000.302 5075 751.607	5076000302 5075751607
Gripper	5282 000.018	5282000018
TS50 pipetting tool	5280 000.010	5280000010
TM50-8 pipetting tool	5280 000.215	5280000215
TM1000-8 pipetting tool	5280 000.258	5280000258
ReservoirRack for epMotion®	5075 754.002	5075754002
PlateReader AF2200	6141 000.002	6141000002
Galaxy® 48 R incubator	C048R-230-000	C048R-230-000
epT.I.P.S.® Motion 50 µL Filter	0030 015.215	0030015215
epT.I.P.S.® Motion 1000 µL Filter	0030 015.258	0030015258
epMotion® Reservoir 30 mL 100 mL	0030 126.505 0030 126.513	0030126505 0030126513
Reservoir Rack Module TC, for use in epMotion® Reservoir Racks, temperable, 4 x Eppendorf Safe-Lock Tubes 0.5/1.5/2.0 mL	5075 799.081	5075799081
Eppendorf Safe-Lock Tubes, 1.5 mL	0030 120.086	0030120086
Eppendorf Deepwell Plate 96/1000 µL	0030 502.205	0030502205
Cell Imaging Plate	0030 741.013	0030741013

Your local distributor: www.eppendorf.com/contact

Eppendorf AG · 22331 Hamburg · Germany
eppendorf@eppendorf.com · www.eppendorf.com

www.eppendorf.com

Vybrant® and Molecular Probes® are registered trademarks of Molecular Probes, Inc., USA. Life Technologies® is a registered trademark of Life Technologies Corporation, USA. Enzo Life Sciences® is a registered trademark of Enzo Biochem, Inc., USA. CellTiter-Blue® and Promega® are registered trademarks of Promega Corporation, USA. CytoTox-Fluor™ is a trademark of Promega Corporation, USA. Umonium³⁸⁸ is a registered trademark of Etienne Huckert, Belgium.

Eppendorf®, the Eppendorf logo, epMotion® and epT.I.P.S.® are registered trademarks of Eppendorf AG, Germany. Galaxy® is a registered trademark of Eppendorf, Inc. USA. U.S. Design Patents are listed on www.eppendorf.com/ip. All rights reserved, including graphics and images. Copyright © 2014 by Eppendorf AG, Germany.

Methods are intended for molecular research applications. They are not intended, verified or validated for use in the diagnosis of disease or other human health conditions.